Results 131 to 140 of about 86,974 (242)

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen   +3 more
wiley   +1 more source

Dexrazoxane protects against doxorubicin‐induced cardiotoxicity in susceptible human living myocardial slices: A proof‐of‐concept study

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose The increasing number of cancer survivors has caused growing concern over chemotherapy‐induced cardiotoxicity. This study aimed to investigate a novel human model of cardiotoxicity and explore cardioprotection. Experimental Approach Living myocardial slices (LMS) were obtained from explanted end‐stage heart failure ...
Jort S. A. van der Geest   +15 more
wiley   +1 more source

Incessant Nonsustained Ventricular Tachycardia Unmasking Pulmonary Embolism. [PDF]

open access: yesJACC Case Rep
Sóñora-López S   +7 more
europepmc   +1 more source

Assessment of the molecular mechanisms of drug‐induced hidden cardiotoxicity by a multi‐omics approach: The example of rofecoxib

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose Hidden cardiotoxicity is defined as drug‐induced cardiotoxicity that becomes obvious only in the presence of comorbidities. However, the molecular mechanisms of hidden cardiotoxicity are not always known. Therefore, unbiased multi‐omics approaches could assist in revealing regulatory pathways.
Bennet Y. Weber   +12 more
wiley   +1 more source

Role of Histone Deacetylase and Inhibitors in Cardiovascular Diseases

open access: yesCell Proliferation, EarlyView.
HDACs play an important role in the occurrence and development of cardiovascular diseases, such as myocardial hypertrophy, hypertension, and atherosclerosis. HDAC inhibitors have broad prospects for the treatment of CVD, and different HDAC subtypes can act through different mechanisms.
Li‐Ying Zhang   +4 more
wiley   +1 more source

A study of the clinical usefulness of the eMEMO®. [PDF]

open access: yesJ Arrhythm
Nakayama H   +6 more
europepmc   +1 more source

First‐line diagnostic tests to intercept primary heart involvement in systemic sclerosis: Clinical associations from the SPRING‐SIR registry

open access: yesEuropean Journal of Clinical Investigation, EarlyView.
Primary heart involvement (pHI) is a severe but often overlooked complication of systemic sclerosis (SSc), linked to heart failure, arrhythmias and mortality. In a study of 600 patients from the Italian SPRING‐SIR registry, 25% had ECG or echocardiographic signs of pHI at baseline, associated with older age, diffuse skin disease and intestinal symptoms.
Antonio Tonutti   +91 more
wiley   +1 more source

Home - About - Disclaimer - Privacy